**Core Concept**
Anticoagulants are medications used to prevent blood clots and thrombosis. Routine coagulation profile monitoring post-dosing is essential for many anticoagulants to adjust dosages and prevent bleeding complications. However, some anticoagulants have a more predictable pharmacokinetic profile, making routine monitoring unnecessary.

**Why the Correct Answer is Right**
Apixaban is a direct oral anticoagulant (DOAC) that selectively inhibits Factor Xa. Its pharmacokinetics are predictable, with a narrow therapeutic index and minimal drug interactions. Apixaban's efficacy and safety are well-established, and its metabolism is primarily hepatic, with minimal renal excretion. This predictable profile allows for fixed dosing without the need for routine coagulation profile monitoring.

**Why Each Wrong Option is Incorrect**
**Option A:** Warfarin is an indirect oral anticoagulant that inhibits the synthesis of vitamin K-dependent clotting factors. Its pharmacokinetics and pharmacodynamics are highly variable, and routine monitoring of the international normalized ratio (INR) is essential to adjust dosages and prevent bleeding complications.

**Option B:** Dabigatran is another DOAC that selectively inhibits thrombin. While its pharmacokinetics are more predictable than warfarin, dabigatran does require routine coagulation profile monitoring, particularly in patients with renal impairment.

**Option C:** Rivaroxaban is a DOAC that selectively inhibits Factor Xa, similar to apixaban. However, rivaroxaban requires routine coagulation profile monitoring, particularly in patients with renal impairment or those taking interacting medications.

**Clinical Pearl / High-Yield Fact**
When selecting an anticoagulant for a patient, consider their renal function, drug interactions, and comorbidities. Fixed-dose DOACs like apixaban may offer a more convenient and safer option, but always monitor for bleeding and thrombosis complications.

**Correct Answer:** C. Apixaban